IP Library Granted Patent US 8,728,510
Granted Patent B1
US 8,728,510 · App. 10/098,686 · Granted May 20, 2014

Biocompatible carrier containing a bioadhesive material

Inventor: Wouter E. Roorda (Palo Alto, CA)
Assignee: Advanced Cardiovascular Systems, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,510
App. No.
10/098,686
Granted
May 20, 2014
Kind
B1
Abstract

A biocompatible carrier for delivery of a therapeutic substance or an active agent is disclosed. The carrier contains a bioadhesive material allowing for increased residence time of the active agent at the treatment site.

Claims (13)

1. A coating composition for introducing a therapeutic compound to a blood vessel, the composition comprising:

a therapeutic compound;

a carrier made from a carrier material for delivery of the therapeutic compound, wherein the carrier material is selected from the group consisting of polyphosphoesters, and

a bioadhesive material contained in the carrier,

wherein the carrier material and the bioadhesive material are a blood compatible formulation,

the bioadhesive material comprises sodium starch glycolate,

and

the composition is coated on the outside of a balloon catheter.

2. The coating composition according to claim 1 , wherein the therapeutic compound is selected from those that ameliorate restenosis of a blood vessel.

3. The coating composition according to claim 1 , wherein the coating composition has a greater affinity for the blood vessel wall than the catheter.

4. The coating composition according to claim 1 , wherein the therapeutic substance is a member of at least one genus selected from the group consisting of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic, and antioxidant substances.

5. The coating composition according to claim 1 , wherein the therapeutic substance is selected from the group consisting of actinomycin D, dactinomycin, actinomycin IV, actinomycin I, actinomycin X1, actinomycin C, paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, mitomycin, sodium heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, bivalirudin, angiopeptin, captopril, cilazapril, lisinopril, nifedipine, colchicine, lovastatin, nitroprusside, suramin, triazolopyrimidine, nitric oxide, permirolast potassium, rapamycin, dexamethasone, and combinations thereof.

6. The coating composition according to claim 1 , wherein the therapeutic substance comprises a member of the group consisting of paclitaxel, docetaxel, sodium heparin, rapamycin, and dexamethasone.

Assignments (2)
CHANGE OF NAME Recorded Apr 23, 2014
From: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
To: ABBOTT CARDIOVASCULAR SYSTEMS INC.
Reel/Frame 032745/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2002
From: ROORDA, WOUTER E.
To: ADVANCED CARDIOVASCULAR SYSTEMS, INC.
Reel/Frame 012719/0327 →